GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Bio-heart Biological Technology Co Ltd (HKSE:02185) » Definitions » Asset Turnover

Shanghai Bio-heart Biological Technology Co (HKSE:02185) Asset Turnover : 0.00 (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Shanghai Bio-heart Biological Technology Co Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Shanghai Bio-heart Biological Technology Co's Revenue for the six months ended in Jun. 2024 was HK$0.00 Mil. Shanghai Bio-heart Biological Technology Co's Total Assets for the quarter that ended in Jun. 2024 was HK$869.21 Mil. Therefore, Shanghai Bio-heart Biological Technology Co's Asset Turnover for the quarter that ended in Jun. 2024 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Shanghai Bio-heart Biological Technology Co's annualized ROE % for the quarter that ended in Jun. 2024 was -6.97%. It is also linked to ROA % through Du Pont Formula. Shanghai Bio-heart Biological Technology Co's annualized ROA % for the quarter that ended in Jun. 2024 was -6.40%.


Shanghai Bio-heart Biological Technology Co Asset Turnover Historical Data

The historical data trend for Shanghai Bio-heart Biological Technology Co's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Bio-heart Biological Technology Co Asset Turnover Chart

Shanghai Bio-heart Biological Technology Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
- - - - -

Shanghai Bio-heart Biological Technology Co Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Shanghai Bio-heart Biological Technology Co's Asset Turnover

For the Biotechnology subindustry, Shanghai Bio-heart Biological Technology Co's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Bio-heart Biological Technology Co's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Bio-heart Biological Technology Co's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Shanghai Bio-heart Biological Technology Co's Asset Turnover falls into.


';

Shanghai Bio-heart Biological Technology Co Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Shanghai Bio-heart Biological Technology Co's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0/( (1096.077+894.601)/ 2 )
=0/995.339
=0.00

Shanghai Bio-heart Biological Technology Co's Asset Turnover for the quarter that ended in Jun. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Jun. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Jun. 2024 ))/ count )
=0/( (894.601+843.811)/ 2 )
=0/869.206
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Shanghai Bio-heart Biological Technology Co  (HKSE:02185) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Shanghai Bio-heart Biological Technology Co's annulized ROE % for the quarter that ended in Jun. 2024 is

ROE %**(Q: Jun. 2024 )
=Net Income/Total Stockholders Equity
=-55.614/798.244
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-55.614 / 0)*(0 / 869.206)*(869.206/ 798.244)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*1.0889
=ROA %*Equity Multiplier
=-6.40 %*1.0889
=-6.97 %

Note: The Net Income data used here is two times the semi-annual (Jun. 2024) net income data. The Revenue data used here is two times the semi-annual (Jun. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Shanghai Bio-heart Biological Technology Co's annulized ROA % for the quarter that ended in Jun. 2024 is

ROA %(Q: Jun. 2024 )
=Net Income/Total Assets
=-55.614/869.206
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-55.614 / 0)*(0 / 869.206)
=Net Margin %*Asset Turnover
= %*0
=-6.40 %

Note: The Net Income data used here is two times the semi-annual (Jun. 2024) net income data. The Revenue data used here is two times the semi-annual (Jun. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Shanghai Bio-heart Biological Technology Co Asset Turnover Related Terms

Thank you for viewing the detailed overview of Shanghai Bio-heart Biological Technology Co's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Bio-heart Biological Technology Co Business Description

Traded in Other Exchanges
N/A
Address
No.590 Ruiqing Road, Room 302, 3rd Floor, Building 4 & Building 6, East Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, CHN
Shanghai Bio-heart Biological Technology Co Ltd is engaged in the research and development of bioresorbable scaffold (BRS) products and the renal denervation (RDN) system. The company is a interventional cardiovascular device company in China, and locate in Shanghai Zhangjiang Hi-Tech Park Medical Device Industrial Park. Focused on two therapies, bioresorbable scaffolds (BRS) and renal denervation (RDN), addressing the unmet medical needs of Chinese patients for the treatment of coronary and peripheral artery diseases and uncontrolled hypertension.
Executives
Tpg Operating Group Ii, L.p. 2201 Interest of corporation controlled by you
Chen Hao 2201 Interest of corporation controlled by you
Zhu Linan 2201 Interest of corporation controlled by you
Wang Nengguang 2201 Interest of corporation controlled by you
Union Season Holdings Limited 2201 Interest of corporation controlled by you
Sk China Company Limited 2201 Interest of corporation controlled by you
Right Lane Limited 2201 Interest of corporation controlled by you
Proud Solar Limited 2201 Interest of corporation controlled by you
Magic Grace Limited 2101 Beneficial owner
Loft Success Investments Limited 2201 Interest of corporation controlled by you
Lc Healthcare Fund Ii, L.p. 2201 Interest of corporation controlled by you
Lc Healthcare Fund Ii Gp Limited 2201 Interest of corporation controlled by you
Lc Fund Gp Limited 2201 Interest of corporation controlled by you
Great Unity Fund I, L.p. 2201 Interest of corporation controlled by you
Lian Xiang Kong Gu Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you

Shanghai Bio-heart Biological Technology Co Headlines

No Headlines